Skip to main content

Table 1 Count of viable PBMC collected before and after the first cycle of DOX infusion from 8 BC patients undergoing NAC and recruited in ARMAGEDDON-01 protocol

From: Impact of doxorubicin-loaded ferritin nanocages (FerOX) vs. free doxorubicin on T lymphocytes: a translational clinical study on breast cancer patients undergoing neoadjuvant chemotherapy

 

PBMC/mL of blood

Ratio

Mean ± St.dev (× 106)

Before DOX

1.24 ± 0.67

After DOX

0.53 ± 0.15

0.48 ± 0.15